Fennec Pharmaceuticals Inc expected to post a loss of 3 cents a share - Earnings Preview

Fennec Pharmaceuticals

30/07/2024 20:36

* Fennec Pharmaceuticals Inc  FENC.OQ   FENC.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 1 (estimated) for the period ending June 30 2024
    * The Research Triangle Park North Carolina-based  company
is
expected to report a 232.3% increase in revenue to $11.049
million from $3.33 million a year ago, according to the mean
estimate from 6 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Fennec Pharmaceuticals
Inc is
for a loss of 3 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fennec
Pharmaceuticals Inc is $16.50​, above​ its last closing price
of $6.27. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  0.30        0.26       0.47      Beat    79.4
 Dec. 31 2024  -0.05       -0.02      -0.10     Missed  -410.2
 Sep. 30 2023  -0.12       -0.12      -0.07     Beat    41.7​
 Jun. 30 2023  -0.17       -0.16      -0.21     Missed  -34.2
 ​​Mar.        -0.21       -0.21      -0.23     Missed  -9.6
 31 2023                                                
 Dec. 31 2022  -0.20       -0.26      -0.26     Met     1.8​
 Sep. 30 2022  -0.18       -0.18      -0.31     Missed  -70.6
 Jun. 30 2022  -0.15       -0.14      -0.19     Missed  -39
 This summary was machine generated July 30 at 19:36 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)